Security record · archived quarter
ACAD
ACADIA Pharmaceuticals Inc. · Healthcare · Biotechnology
2Tracked holders
0Δ holders
366.33KShares held
$7.36MReported value
+0New positions
−0Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 366.33K | $7.36M | n/a | n/a |
| Q2 2026 | 122 | +9 | 91.00M | $2.30B | +11 | −1 |
| Q1 2026 | 115 | -3 | 85.30M | $1.90B | +4 | −8 |
| Q4 2025 | 119 | 0 | 93.96M | $2.51B | +1 | n/a |
| Q3 2025 | 23 | +1 | 66.53M | $1.42B | +1 | −1 |
| Q2 2025 | 20 | +2 | 61.51M | $1.33B | +2 | n/a |
| Q1 2025 | 15 | 0 | 22.54M | $374.41M | n/a | n/a |
| Q4 2024 | 15 | +1 | 20.32M | $372.93M | +1 | n/a |
| Q3 2024 | 13 | -1 | 13.63M | $209.57M | n/a | −1 |
| Q2 2024 | 14 | n/a | 19.35M | $314.37M | n/a | n/a |
Who holds it · Q3 2026
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Assenagon Asset Management S.A. | 334.56K | +694.6% | $6.74M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 2 | Wealth Enhancement Advisory… | 31.77K | +2.5% | $622,155 | 0.0% | ▲ Add | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 337 holders, 164.47M shares, $3.62B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q3 2026 ·
Methodology ·
Get this via the API